Kura Oncology announced the publication of a study in the journal Blood detailing the discovery and preclinical development of ziftomenib, a menin inhibitor approved by the FDA in 2025 for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The study highlights ziftomenib's potent and selective inhibition of the menin-KMT2A interaction, its activity against resistance-associated mutations, and its effectiveness in multiple leukemia models. These findings support ziftomenib's potential as a foundational therapy across genetically defined acute leukemias, with ongoing efforts to expand its use in combination with other treatments. Kura Oncology continues clinical development to broaden ziftomenib's benefit to more patients with menin-dependent leukemias.
Nebius Group N.V. reported a breakthrough quarter by securing AI cloud contracts priced at $20-25 million per megawatt, doubling previous revenue targets. The company raised its contracted power guidance to 5 GW, projecting over $100 billion in annua...
In Q2 2026, three leading investors showed contrasting moves on NVIDIA: David Tepper increased his stake, signaling confidence in AI growth; Dan Loeb fully exited, reallocating to Alphabet; George Soros hedged his large long position by buying puts, ...
Bitcoin's Coinbase Bitcoin Premium Index has remained negative for 90 days, indicating that Bitcoin trades at a lower price on Coinbase compared to Binance. This sustained negative premium reflects ongoing selling pressure in the US market, despite B...
NVIDIA and SpaceX have announced a strategic partnership to build a massive AI computing infrastructure, targeting 10 gigawatts of AI compute capacity by 2027. SpaceX will use NVIDIA's GPUs exclusively, with NVIDIA backing a $500 billion financing pl...
Solana's network added $378.2 million in tokenized U.S. Treasury bills over the past month, exceeding Ethereum's $272.2 million increase by about $106 million. Despite this strong growth in tokenized assets, Solana's price has weakened, trading near ...
